ResMed Inc.  

(Public, NYSE:RMD)   Watch this stock  
Find more results for resmed
50.09
+0.01 (0.02%)
Real-time:   12:38PM EDT
NYSE real-time data - Disclaimer
Currency in USD
Range 50.00 - 50.81
52 week 29.82 - 51.40
Open 50.10
Vol / Avg. 172,896.00/1.02M
Mkt cap 7.14B
P/E 23.59
Div/yield 0.17/1.36
EPS 2.12
Shares 142.47M
Beta 0.70
Inst. own 55%
Jul 29, 2013
Q4 2013 ResMed Inc. Earnings Release Add to calendar
Apr 25, 2013
Q3 2013 ResMed Inc. Earnings Conference Call - Webcast
Apr 25, 2013
Q3 2013 ResMed Inc. Earnings Release
Mar 13, 2013
ResMed Inc. at Barclays Healthcare Conference - Webcast
Feb 26, 2013
ResMed Inc. at Citi Global Healthcare Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '13) 2012
Net profit margin 22.14% 18.62%
Operating margin 25.05% 21.22%
EBITD margin - 26.67%
Return on average assets 14.48% 12.12%
Return on average equity 19.35% 15.27%
Employees 3,700 -
Carbon Disclosure Rating - -

Address

9001 Spectrum Center Blvd.
SAN DIEGO, CA 92123
United States - Map
+1-858-8365000 (Phone)
+1-858-8365501 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Discussion Group - Google Finance

Description

ResMed Inc., (ResMed) is a holding company for the ResMed Group. The Company, through its subsidiaries, is a developer, manufacturer and distributor of medical equipment for treating, diagnosing, and managing sleep-disordered breathing and other respiratory disorders. Sleep-disordered breathing (SDB) includes obstructive sleep apnea (OSA), and other respiratory disorders that occur during sleep. The Company has developed a number of products for SDB and other respiratory disorders including airflow generators, diagnostic products, mask systems, headgear and other accessories. Its manufacturing operations are located in Australia, Singapore, France, Germany, Malaysia and the United States. Its major distribution and sales sites are located in the United States, Germany, France, the United Kingdom, Switzerland, Australia, Japan, Norway and Sweden. On July 5, 2011, the Company acquired the remaining 87% of BiancaMed Ltd. On August 1, 2011 the Company acquired Gruendler GmbH.

Officers and directors

Peter C. Farrell Ph.D. Non-Executive Chairman of the Board
Age: 70
Bio & Compensation  - Reuters
Robert D. Douglas President, Chief Operating Officer
Age: 53
Bio & Compensation  - Reuters
Michael J. Farrell Chief Executive Officer, Director
Age: 40
Bio & Compensation  - Reuters
Brett Sandercock Chief Financial Officer
Age: 45
Bio & Compensation  - Reuters
Don Darkin President - Sleep-disordered Breathing Strategic Business Unit
Age: 59
Bio & Compensation  - Reuters
Jim Hollingshead President - Americas
Age: 49
Bio & Compensation  - Reuters
Anne Reiser President, Europe
Age: 51
Bio & Compensation  - Reuters
David Pendarvis Chief Administrative Officer, Global General Counsel, Company Secretary
Age: 53
Bio & Compensation  - Reuters
Gary W. Pace Ph.D. Lead Independent Director
Bio & Compensation  - Reuters
Michael A. Quinn Independent Director
Age: 65
Bio & Compensation  - Reuters